Literature DB >> 20390469

Clinical outcome of breast cancer patients with N3a (≥10 positive lymph nodes) disease: has it changed over years?

Gul Basaran1, Cabuk Devrim, Hale B Caglar, Bahadir Gulluoglu, Handan Kaya, Selcuk Seber, Taner Korkmaz, Ferhat Telli, Muharrem Kocak, Faysal Dane, Fulden P Yumuk, Serdar N Turhal.   

Abstract

It has been shown that breast cancer patients with N3a (10 positive lymph nodes) had a poor prognosis. We planned to investigate the clinical outcome BC patients who presented with N3a disease and had no evidence of systemic metastasis at the time of diagnosis. We made a retrospective chart review of breast cancer patients who had ≥10 positive lymph nodes and received adjuvant systemic therapy in Marmara University Hospital between 1998 and 2008. We recorded clinical, pathologic and treatment characteristics of the patients and analyzed the survival outcome. We identified 73 patients with N3a disease who were treated in Marmara University Hospital between 1998 and 2008. The median age was 52. Most (75%) of the patients had invasive ductal histology, 75% had T2/T3 tumors, 36% had grade 3 tumors. The median number of metastatic lymph nodes was 15. Estrogen and progesterone receptors were both positive in 61% and both negative in 16+ tumors. Her-2/neu status was assessed in 68% of the tumors; 18% of patients had 3+ and 50% had negative scores. Six patients had triple negative tumors. All patients except one received adjuvant chemotherapy and radiotherapy. Seventy-four percent of patients received anthracycline/taxane-based chemotherapy. Fifty-nine patients received adjuvant endocrine therapy, 42% them received aromatase inhibitors. Five of the 13 Her-2 positive patients received adjuvant trastuzumab. With a median follow-up of 47 months, 5-year disease and overall survival rates were 66 and 81%, respectively. Twenty-four patients had relapsed and 14 patients died. Her-2 status and the number of lymph nodes (<20 vs. ≥20) had significant impact on disease-free survival in the univariate analysis (P=0.03 and 0.05, respectively) and Her-2 retained its significant impact on disease-free survival in the multivariate analysis (P=0.05). The prognosis of BC patients with N3a disease has changed favorably in the past decade with the current standards of care.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20390469     DOI: 10.1007/s12032-010-9516-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  HER-2 as a target for breast cancer therapy.

Authors:  Michail Ignatiadis; Christine Desmedt; Christos Sotiriou; Evandro de Azambuja; Martine Piccart
Journal:  Clin Cancer Res       Date:  2009-03-15       Impact factor: 12.531

2.  Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.

Authors:  P Fumoleau; F Chauvin; M Namer; R Bugat; M Tubiana-Hulin; J P Guastalla; T Delozier; P Kerbrat; Y Devaux; J Bonneterre; A Filleul; M Clavel
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13.

Authors:  William P Peters; Gary L Rosner; James J Vredenburgh; Elizabeth J Shpall; Michael Crump; Paul G Richardson; Michael W Schuster; Lawrence B Marks; Constance Cirrincione; Larry Norton; I C Henderson; Richard L Schilsky; David D Hurd
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

5.  Long-term prognosis of breast cancer patients with 10 or more positive lymph nodes treated with CMF.

Authors:  C Schmoor; W Sauerbrei; G Bastert; H Bojar; M Schumacher
Journal:  Eur J Cancer       Date:  2001-06       Impact factor: 9.162

6.  The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.

Authors:  G Jabro; D E Wazer; R Ruthazer; R Lum; N Sklar; D Goldman; D Enegess; J Erban
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-05-01       Impact factor: 7.038

7.  Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.

Authors:  Ian F Faneyte; Johannes L Peterse; Harm Van Tinteren; Corina Pronk; Marijike Bontenbal; Louk V A M Beex; Elsken van der Wall; Dick J Richel; Marianne A Nooij; Emile E Voest; Pierre Hupperets; Elisabeth M Ten Vergert; Elisabeth G E de Vries; Sjoerd Rodenhuis; Marc J van de Vijver
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

8.  High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial.

Authors:  A R Zander; N Kröger; C Schmoor; W Krüger; V Möbus; N Frickhofen; B Metzner; W Schultze; W E Berdel; M Koenigsmann; E Thiel; H Wandt; K Possinger; L Trümper; R Kreienberg; M Carstensen; E H Schmidt; F Jänicke; M Schumacher; W Jonat
Journal:  J Clin Oncol       Date:  2004-04-26       Impact factor: 44.544

9.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Authors:  Michele De Laurentiis; Giuseppe Cancello; Diego D'Agostino; Mario Giuliano; Antonio Giordano; Emilia Montagna; Rossella Lauria; Valeria Forestieri; Angela Esposito; Lucrezia Silvestro; Roberta Pennacchio; Carmen Criscitiello; Agnese Montanino; Gennaro Limite; Angelo Raffaele Bianco; Sabino De Placido
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

10.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

View more
  8 in total

1.  Prognostic Factors in Operated Stage IIIC, Pathological N3a Breast Cancer Patients.

Authors:  Ibrahim Turker; Ulku Y Arslan; Ozan Yazici; Ummugul Uyeturk; Berna Oksuzoglu; Burcin Budakoglu; Nuriye Özdemir; Ozlem U Sonmez; Kaan Helvaci; Onur Esbah; Oznur Bal; Ahmet S Ekinci; Nurullah Zengin
Journal:  Breast Care (Basel)       Date:  2014-12       Impact factor: 2.860

2.  Factors influencing the outcome of breast cancer patients with 10 or more metastasized axillary lymph nodes.

Authors:  Jun Sang Lee; Seung Il Kim; So Young Choi; Hyung Seok Park; Jong Seok Lee; Seho Park; Jaseung Koo; Byeong-Woo Park; Kyong Sik Lee
Journal:  Int J Clin Oncol       Date:  2011-03-01       Impact factor: 3.402

3.  Clinical Outcomes of N3 Breast Cancer: A Real-World Study of a Single Institution and the US Surveillance, Epidemiology, and End Results (SEER) Database.

Authors:  Xiang Ai; Xin Liao; Junyan Li; Peng Tang; Jun Jiang
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

4.  The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

Authors:  A B D'Assoro; T Liu; C Quatraro; A Amato; M Opyrchal; A Leontovich; Y Ikeda; S Ohmine; W Lingle; V Suman; J Ecsedy; I Iankov; A Di Leonardo; J Ayers-Inglers; A Degnim; D Billadeau; J McCubrey; J Ingle; J L Salisbury; E Galanis
Journal:  Oncogene       Date:  2013-01-21       Impact factor: 9.867

5.  Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.

Authors:  Emre Koca; Taha Y Kuzan; Omer Dizdar; Taner Babacan; Ilyas Sahin; Erhan Ararat; Kadri Altundag
Journal:  Med Oncol       Date:  2013-06-01       Impact factor: 3.064

6.  Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes.

Authors:  Sang-Won Kim; Doo Ho Choi; Seung Jae Huh; Won Park; Seok Jin Nam; Seok Won Kim; Jeong Eon Lee; Young-Hyuck Im; Jin Seok Ahn; Yeon Hee Park
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

7.  Metastatic axillary node ratio predicts recurrence and poor long-term prognosis in patients with advanced stage IIIC (pN3) breast cancer.

Authors:  Min Hee Hur; SeungSang Ko
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

8.  Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer.

Authors:  Yun Yeong Kim; Heung Kyu Park; Kyung Hee Lee; Kwan Il Kim; Yong Soon Chun
Journal:  J Breast Cancer       Date:  2016-06-24       Impact factor: 3.588

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.